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SINTESIS, PERENCATAN KOLINESTERASE DAN KAJIAN PENDOKAN 
MOLEKUL TERBITAN PIPERIDON-TERCANTUM  
PIRIMIDINA DAN TIAZOLOPIRIMIDINA 
 
ABSTRAK 
 
Penyakit Alzheimer (AD) adalah demensia yang paling biasa dalam kalangan orang tua. 
Berdasarkan hipotesis kolinergik, kehilangan neuron kolinergik dalam otak pesakit AD 
menyebabkan kemerosotan tahap neurotransmiter asetilkolina (ACh) dan akhirnya 
menyebabkan disfungsi teruk dalam sistem neuropenghantaran kolinergik. Oleh itu, 
meningkatkan tahap ACh adalah kaedah terapeutik yang berpotensi untuk memulihkan 
sebahagian besar kemerosotan ingatan dan disfungsi kognitif pada pesakit AD. 
Pencarian perencat kolinesterase yang baru sedang berjalan di seluruh dunia. 
Diinspirasikan oleh kepentingan biologi terbitan tercantum pirimidina, terutamanya 
dalam perencatan kolinesterase, tujuh puluh empat terbitan tercantum pirimidina  yang 
baru, iaitu piridopirimidina 6(a-l), piridopirimidition 7(a-l), N-etilpiridopirimidition  
8(a-j), N-etilmorfolinopiridopirimidition 9(a-j), pirimidintiol 11(a-l) dan 
thiazolopirimidina 13(a-r) telah disintesiskan dan dinilai bagi perencatan kolinesterase 
mereka terhadap asetilkolinesterase (AChE) dan butirilkolinesterase (BChE). 
 
Menariknya, enam puluh lima daripada tujuh puluh empat sebatian yang dihasilkan 
mempunyai aktiviti perencatan BChE yang poten dengan nilai IC50 yang lebih rendah 
daripada galantamina (IC50=19.34 μM) manakala sepuluh sebatian mempunyai aktiviti 
xxi 
 
perencatan AChE yang lebih tinggi atau setanding dengan galantamina (IC50=2.19 μM). 
Sebatian 13d dan 7e adalah perencat AChE dan BChE yang paling poten dengan nilai 
IC50 0.53 dan 1.18 μM, masing-masing. 
 
Secara umumnya, penggantian moieti karbonil (C=O) dalam siri 6 dengan moieti 
tiokarbonil (C=S) dalam siri 7 telah menambahkan aktiviti perencatan bagi kedua-dua 
AChE dan BChE. Oleh itu, kajian seterusnya telah ditumpukan kepada pengubahsuaian 
terbitan siri 7 yang berpotensi. Sebatian dalam siri 8(a-j) dan 9(a-j) yang dihasilkan oleh 
pencantuman moieti etil atau etilmorfolino kepade NH bebas daripade gelang piperidon 
dalam siri 7 telah memaparkan potensi perencatan AChE dan BChE yang lebih baik. 
Tambahan pula, sebatian dalam siri 11, yang dihasilkan oleh penukaran moieti 
tiokarbonil (C=S) dalam siri 7 dengan entiti tiol (C-SH) telah menghasilkan peningkatan 
kecil dalam aktiviti perencatan bagi kedua-dua AChE dan BChE. Walaupun 
pengubahsuaian piridopirimidotion yang tersebut dalam siri 7, kebanyakan terbitan 
dalam siri 8, 9 dan 11 lebih cenderung kepada BChE dan secara amnya lebih lemah 
dalam aktiviti perencatan AChE. Oleh itu, satu siri thiazolopirimidina (siri 13) telah 
disintesis. Sebatian dalam siri 13 bukan sahaja menunjukkan potensi perencatan 
kolinesterase yang lebih tinggi tetapi juga menunjukkan pemilihan kepada AChE yang 
lebih baik berbanding dengan siri yang lain. Tambahan pula, sebatian 13(a-d) juga 
menunjukkan sifat-sifat perencatan dual terhadap kedua-dua enzim AChE dan BChE. 
 
Perencat AChE dan BChE yang paling aktif  yang menunjukkan potensi lebih baik atau 
setanding dengan galantamina telah didokkan ke dalam tapak aktif AChE dan BChE 
xxii 
 
untuk tujuan penyiasatan orientasi dan ciri-ciri interaksi pengikatan mereka. Perencat ini 
lebih cenderung menunjukkan interaksi hidrofobik dan π, π-menyusun dengan sisa-sisa 
asid amino aromatik yang membarisi tapak anionik periferal (contohnya Tyr70, Tyr121, 
Trp279 dan Tyr334 dalam TcAChE) dan tapak pengikatan kolina (contohnya Phe330 
dan Trp84 dalam TcAChE) pada enzim yang mungkin mencegah penyisipan dan 
hidrolisis substrat di tapak mangkin enzim yang menyebabkan aktiviti perencat 
kolinesterase yang kuat. Ramalan ciri-ciri fizikokimia bagi kebanyakan perencat yang 
paling aktif telah mendedahkan bahawa semua sebatian ini adalah molekul organik yang 
kecil dan sangat lipofilik, oleh itu mempunyai keupayaan yang baik untuk melalui 
halangan darah otak dan aktiviti sistem saraf pusat serta penyerapan oral yang baik 
dalam saluran gastrousus. Antaranya, sebatian 7e, 7i dan 8a menunjukkan sifat-sifat 
fizikokimia yang paling memuaskan dan boleh dipertimbangkan sebagai calon drug 
yang berpotensi. 
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SYNTHESIS, CHOLINESTERASE INHIBITORY ACTIVITY AND 
MOLECULAR DOCKING STUDY OF PIPERIDONE-GRAFTED PYRIMIDINE 
AND THIAZOLOPYRIMIDINE DERIVATIVES  
 
ABSTRACT 
 
Alzheimer’s disease (AD) is the most common form of dementia among the elderly 
people. Based on the cholinergic hypothesis, loss of cholinergic neurons in AD patients’ 
brain leads to the decline of acetylcholine (ACh) neurotransmitter level and eventually 
causes severe dysfunctions in the cholinergic neurotransmission. Thus, increasing the 
ACh levels is a promising therapeutic approach to restore the substantial impairment of 
memory and cognitive dysfunctions in AD patients. The search for new cholinesterase 
inhibitors is still ongoing worldwide. Inspired by the biological significance of 
pyrimidine-grafted derivatives, especially in cholinesterase inhibition, seventy-four 
novel pyrimidine embedded derivatives, namely pyridopyrimidines 6(a-l), 
pyridopyrimidothiones 7(a-l), N-ethyl-pyridopyrimidothiones 8(a-j), N-ethylmorpholino 
pyridopyrimidothiones 9(a-j), pyrimidinethiols 11(a-l) and thiazolopyrimidines 13(a-r) 
were synthesized and evaluated for their cholinesterases inhibitory potential against 
acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).  
 
Interestingly, sixty-five out of seventy-four synthesized compounds had potent BChE 
inhibitory activities with IC50 values lower than galanthamine (IC50=19.34 µM) while 
ten compounds had higher or comparable AChE inhibitory activity to that of 
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galanthamine (IC50=2.19 µM). Compounds 13d and 7e were the most potent AChE and 
BChE inhibitors with IC50 values of 0.53 and 1.18 µM, respectively.  
 
Generally, replacement of carbonyl (C=O) moiety in series 6 with thiocarbonyl (C=S) 
moiety in series 7, improved both AChE and BChE inhibitory activities. Therefore, 
further studies were focused on the modifications of potentially active derivatives of 
series 7. The compounds in series 8(a-j) and 9(a-j), afforded by attachments of ethyl or 
ethylmorpholino moieties to the free NH of piperidone ring in series 7 displayed better 
AChE and BChE inhibition potencies.  Furthermore, compounds in series 11, prepared 
by the conversion of the thiocarbonyl (C=S) moiety in series 7 with thiol (C-SH) entity 
also resulted in slight improvements in both AChE and BChE inhibitory activities. 
Despite the aforementioned modifications on pyridopyrimidothiones in series 7, most of 
derivatives in series 8, 9 and 11 had more selectivity toward BChE and generally weaker 
AChE inhibitory activity. Therefore, a series of thiazolopyrimidines (series 13) were 
synthesized. The compounds in series 13 not only showed higher cholinesterases 
inhibition potencies but also displayed better selectivity towards AChE compared to the 
other series. Moreover, compounds 13(a-d) also displayed dual inhibitory properties, 
against both AChE and BChE. 
 
The most active AChE and BChE inhibitors displaying more or comparable potency to 
that of galanthamine were docked into the active sites of AChE and BChE to investigate 
their orientations and binding interactions characteristics. These inhibitors preferentially 
displayed hydrophobic and π,π-stacking interactions with aromatic amino acid residues 
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composing peripheral anionic site (e.g. Tyr70, Tyr121, Trp279 and Tyr334 in TcAChE)  
and choline binding site (e.g. Phe330 and Trp84 in TcAChE) of the enzymes that 
plausibly prohibit insertion and hydrolysis of substrate at catalytic site of the enzymes 
and ensue strong cholinesterase inhibitory activities. Physicochemical properties 
predictions for the most active inhibitors revealed that all these compounds are small 
organic molecules, highly lipophilic, thus having good ability to pass through blood 
brain barrier and central nervous system activity as well as good oral absorption in the 
gastrointestinal tract. Among them, ccompounds 7e, 7i and 8a displayed the most 
favourable physicochemical properties and may be considered as promising drug 
candidates. 
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CHAPTER 1 
INTRODUCTION 
 
Alzheimer’s disease (AD) is a prevalent, irreversible neurodegenerative disorder that 
according to the World Alzheimer’s Report, till now affected more than 35 million 
people worldwide (Prince et al., 2011). The etiology of AD is not completely 
understood. The appearance of extracellular β-amyloid plaques and formation of 
intracellular neurofibrillary tangles are considered as main pathological hallmarks of 
this disease (Pimplikar, 2009). AD is clinically characterized by progressive cognitive 
impairments, loss of memory and learning disabilities along with a diverse range of 
neuropsychiatric symptoms (Ferri et al., 2004).  
 
Based on the so-called cholinergic hypothesis, loss of cholinergic neurons in the 
forebrain, cortex and hippocampus of AD patients’ brain lead to decline in acetylcholine 
(ACh) neurotransmitter level, which eventually causes memory and cognitive 
impairments due to severe dysfunctions in cholinergic neurotransmission system 
(Bartus, 2000). Two cholinesterases, acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE) are responsible for degradation and regulation of 
acetylcholine in human body, however they differ in kinetics and substrate selectivity 
(Giacobini, 2004). Acetylcholinesterase (AChE) plays a pivotal role in central and 
peripheral nervous systems to terminate the nerve impulse transmissions from the nerve 
cell to postsynaptic membrane or from the nerve cell to skeletal muscles. On the other 
hand, the role of butyrylcholinesterase (BChE) is not clearly known, although it is 
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proposed that this non-specific cholinesterase, protects AChE by hydrolyzing harmful 
toxins that may damage or deactivate AChE (Giacobini, 2003). 
 
The active sites of these two cholinesterase are located at the bottom of a 20 Å long, 
narrow gorge comprising five important regions to accommodate and hydrolyze the 
substrate, namely the catalytic triad, oxyanion hole, choline binding site, acyl binding 
pocket and peripheral anionic site. While the overall structure of human BChE is similar 
to that of human AChE, the active site of BChE has many of the channel-lining 
aromatic residues replaced by residues with aliphatic side chains, such as leucine (Leu) 
and valine (Val), making BChE more proper to accommodate bulkier substrates and 
inhibitors (Nicolet et al., 2003). Acetylcholine or inhibitors guidance inside the gorge is 
facilitated by hydrophobic interactions with aromatic amino acid residues lining the 
gorge wall (Koellner et al., 2002).  
 
Hitherto, clinically approved treatments for AD are limited to cholinesterase inhibitors 
(e.g. donepezil, galanthamine, rivastigmine, huperzine A), which act by inhibiting 
cholinesterases and also N-methyl d-aspartate receptor antagonists (e.g. memantine), 
which act at the glutaminergic pathway (Farlow et al., 2009). Organic synthesis is a 
valuable tool to prepare a library of drug candidate molecules and their bioactivity 
guided modifications to amplify the desired activities and to minimize or eliminate the 
unwanted properties for extensive biological, pharmacological and animal studies 
(Lednicer, 2009). Among the biologically active lead compounds, pyrimidine grafted 
entities were found to possess a wide range of biological properties such as 
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antibacterial, anti-inflammatory, antiviral, anti HIV (Lednicer, 2009) as well as 
cholinesterase inhibitory activity (Mohamed et al., 2010). 
 
Problem statement 
Currently, the most widely used approach for symptomatic treatment and/or alleviation 
of severe cognitive impairments in the individuals suffering from AD is limited to 
cholinesterase inhibitor drugs such as donepezil or galanthamine. Despite the 
tremendous efforts in search of novel disease modifying agents working via β-amyloid 
or tau pathways, none is clinically available due to their adverse effects. Moreover, 
limitation of potent cholinesterase inhibitor drugs, keeps the search for new inhibitors 
going worldwide. On this note, in the present study, novel piperidone grafted 
pyrimidine and thiazolopyrimidine derivatives were synthesized and evaluated for their 
cholinesterases inhibitory activities, in search for new cholinesterase inhibitors. 
Furthermore, their molecular interactions and orientation with cholinesterase were 
studied. 
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Objectives 
The aims of the present study are as follow: 
1. To synthesize, isolate, characterize and elucidate the structure of novel piperidone 
grafted pyrimidines, pyrimidinethiols and thiazolopyrimidine derivatives. 
2. To evaluate the cholinesterases inhibitory activities of synthesized compound 
against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). 
3. To investigate the structure-activity relationship (SAR) studies of the synthesized 
compounds. 
4. To investigate the orientations and binding interaction types of the most active 
inhibitors inside the active site gorge of AChE and BChE by molecular docking 
analysis and predict their relevant physicochemical properties. 
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Figure 1.1. Work flow
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Alzheimer’s disease 
 
2.1.1. Prevalence, incidence and impact of Alzheimer’s disease 
According to the 2012 World Alzheimer report, there are an estimated of 35.6 million 
people with dementia worldwide (Prince et al., 2011). Alzheimer’s disease (AD) is the 
most common form of dementia, which accounts for 60 to 80 % of dementia cases in 
the elderly (Beckett et al., 2010). This number doubles every 20 years, estimated to 
reach 65.7 million by 2030 and 115.4 million by 2050. Approximately 58% of people 
with dementia live in developing countries, but by 2050 this will rise to 71%. The 
fastest growth in the elderly population is taking place in China, India, and their south 
Asian and western Pacific neighbours (Alzheimer's Disease International, 2013).   
 
As the population ages, the prevalence of AD and related dementias increase. In United 
States, one in eight people age 65 and older (13 %) show symptoms of AD. Almost half 
of people age of 85 and older (45%) are suffering from AD (Hebert et al., 2003). 
Researches also revealed that, women are more affected by AD and other dementias 
than men. Based on estimations, 16% of women at age of 71 and older have AD or 
other dementias compared to 11% of men (Plassman et al., 2007). This larger 
proportion of older women having AD or other dementias is basically due to the fact 
that women live longer than men (Seshadri et al., 1997). 
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Prevalence and incidence studies showed that people with higher years of education 
seem to be at lower risk for AD and other dementias than those with less years of 
education (Gurland et al., 1999). Researchers believed that higher level of education 
provides a “cognitive reserve” that enables individuals to tolerate the changes in the 
brain which could ensue AD or another dementia (Roe et al., 2007).  
 
Despite affecting a comparatively lesser number of people that other chronic diseases 
such as diabetes mellitus and heart related diseases, the impact of AD on social and 
economic burden, due to its huge financial resource consumption (e.g. Medicare and 
caregivers costs) is tremendous. In 2012, in United States more than 15 million family 
members and other caregivers provided an estimated 17.5 billion hours of care to people 
with AD with a value of more than USD 216 billion. Medicare payments for services to 
beneficiaries age 65 years and older with AD are three times more than the payments 
for beneficiaries without these conditions. Total payments in 2013 for health care, long-
term care, and hospice services for people age 65 years and older with dementia are 
expected to be USD 203 billion (Mebane-Sims, 2009).  
 
2.1.2. Clinical symptoms of Alzheimer’s disease 
AD is manifested by a progressive impairment of cognitive functions including memory 
loss that disrupts daily life, challenges in planning and solving the problems, confusion 
with time or places and withdrawal from work or social activities. At advanced stages of 
the disease, AD patients also exhibit behavioural disturbances including agitation, 
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irritability, anxiety, delusions and depression resulting in morbidity and eventual 
mortality (Ferri et al., 2006). 
 
2.1.3. Pathogenesis of Alzheimer’s disease 
The main and dominant pathological changes of the brain believed to contribute in the 
development of AD are the accumulation of β-amyloid (Aβ) plaques outside the 
neurons and neuroﬁbrillary tangles, composed of hyper-phosphorylated tau proteins, 
inside the neurons.  
 
The β-amyloid plaques first appear in the frontal cortex, and then spread over the entire 
cortical region, while hyper-phosphorylated tau and insoluble tangles initially appear in 
the limbic system and then progresses to the cortical region (Pimplikar, 2009). The 
pathogenesis of AD is explained by various hypotheses such as amyloid, tau and 
cholinergic hypotheses.  
 
2.1.3.1. Amyloid hypothesis 
Although the exact cause of AD has been the subject of considerable debate, the 
amyloid hypothesis remains one of the best defined and most studied conceptual 
framework for AD (Pimplikar, 2009). As originally proposed in the early 90s, the 
accumulation of hydrophobic amyloid-β peptides outside the neurons in basal forebrain 
due to amyloid precursor protein (APP) over expressed cleavage results in aggregation 
and formation of insoluble plaques (senile plaques), which trigger a cascade of 
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deleterious changes, resulting in neuronal death and thus causing AD (Hardy et al., 
1992). 
 
It is also proposed that basal forebrain cholinergic neurotransmission functions (e.g. 
ACh regulation and release as well as receptor signalling) are impaired by these 
neurotoxic plaques (Yankner et al., 1990) which is a causal factor for the symptoms of 
AD (Auld et al., 2002). However, further studies showed that plaque load does not 
correlate well with the degree of dementia in humans. Furthermore, many AD patients 
with severely impaired memory showed no plaques at post-mortem analysis (Terry et 
al., 1991). On the other hand, recent advances in neuroimaging techniques have shown 
the presence of huge plaques in cognitively normal people (Nordberg, 2008). 
 
2.1.3.2. Tau hypothesis 
The pioneering findings suggested that tau hyper-phosphorylation could constitute a 
common pathogenic pathway in different neurodegenerative diseases such as AD (Iqbal 
et al., 1986; Wood et al., 1986). Physiologically, high level of abnormal tau proteins 
inside the neurons, form insoluble neurofibrillary tangles that inhibit the transportation 
of nutrients and other essential molecules throughout the cell (Weiner et al., 2012). In 
healthy subjects, tau protein is a component of microtubules representing the internal 
support structures for the transport of nutrients, vesicles, mitochondria and 
chromosomes within the cell. Microtubules also stabilize growing axons, which are 
necessary for the development and growth of neurons (Griffin, 2006).  
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In AD, tau protein is abnormally hyper-phosphorylated and forms insoluble ﬁbrils, 
originating deposits within the cell. This process also contributes to cell death. The 
brain of patients in advanced stages of AD shows dramatic shrinkage from cell loss and 
widespread debris from dead and dying neurons. These pathological hallmarks begin to 
appear decades before symptoms onset and long before the dementia stage is reached 
(Toledo et al., 2012).  
 
2.1.3.3. Cholinergic hypothesis 
Cholinergic hypothesis argues that the activity of choline acetyltransferase, the enzyme 
responsible for the synthesis of ACh remarkably decreases in the cortex and 
hippocampus of AD patient’s brain (Bowen et al., 1976; Davies et al., 1976). 
Diminished ACh synthesis and two other specific function of cholinergic synapses viz. 
depolarization-induced ACh release as well as choline uptake in nerve terminals to 
replenish the acetylcholine synthetic machine (Nilsson et al., 1986) result in loss of 
acetylcholine neurotransmitter levels in these brain regions that eventually leads to 
memory loss and other cognitive symptoms of AD (Bartus, 2000).  
 
2.1.4. Pharmacological management of Alzheimer’s disease 
Presently, there are two classes of drugs being used for the treatment of AD, namely the 
cholinesterase inhibitors and glutamate receptor antagonist. These agents are mainly for 
symptomatic treatment of AD and are widely prescribed to ameliorate cognitive 
impairments in these patients (Weinera et al., 2010). Despite the tremendous efforts in 
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search of novel disease modifying agents working via β-amyloid or tau pathways, none 
are clinically available due to their adverse effects.  
 
2.1.4.1. Acetylcholinesterase inhibitors 
The dominant effect of acetylcholinesterase inhibitors (e.g. galanthamine, donepezil, 
rivastigmine and huperzine A) is to restore the cognitive loss as the prevailing symptom 
in AD. These cognitive improvement makes it possible for the patients to respond more 
appropriately and promptly to the environment and facilitates daily living, thus 
increases their quality of life (Pepeu et al., 2012). Acetylcholinesterase inhibitors 
display consistent but modest clinical efficacy against cognitive decline (Lanctôt et al., 
2003). The inhibition of AChE is currently the most promising and widely used 
approach for treating AD. Researchers also revealed that AChE inhibition could play a 
pivotal role in alleviating amyloid β-peptide (Aβ) plaques deposition inside the brain 
(Inestrosa et al., 1996). 
 
2.1.4.2. N-methyl-d-aspartate (NMDA) receptor antagonists 
To date there is only one N-methyl-d-aspartate (NMDA) receptor antagonist, namely 
memantine, which acts at glutaminergic pathway and being clinically used to treat AD. 
However, its highly undesirable side effects at therapeutic doses, makes cholinesterase 
inhibitors a better choice for symptomatic improvement of AD (Parsons et al., 1999).  
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2.2. Cholinesterase enzymes 
Cholinesterases (ChE’s) are a family of enzymes that catalyze the hydrolysis of ACh 
into choline and acetic acid, an essential process to restore the cholinergic transmission 
inside the brain. There are two types of ChE in a mammalian body differing by their 
functions and substrate specificity: acetylcholinesterase (AChE; EC 3.1.1.7) (Figure 
2.1A) and butyrylcholinesterase (BChE; EC 3.1.1.8) (Figure 2.1B) (Pohanka, 2011).  
 
A                                                                        B 
 
 
 
 
 
 
 
Figure 2.1. Representation of Torpedo californica AChE (A) and human BChE (B) 
(Protein Data Bank, 2013) 
 
2.2.1. Physiological functions 
As shown in Figure 2.2, acetylcholinesterase (AChE) plays a pivotal role in central and 
peripheral nervous systems. The synaptic AChE terminates the nerve impulse 
transmissions from the nerve cell presynaptic membrane to postsynaptic membrane 
through the synaptic gap or from the nerve cell membrane to skeletal muscles through 
fast hydrolysis of acetylcholine (Silman et al., 2005).  
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Butyrylcholinesterase (BChE), which is also known as pseudo-cholinesterase or plasma 
cholinesterase is a non-specific enzyme that hydrolyzes many different choline esters. 
BChE physiological function is still unclear, but due to the wide distribution of ChE 
agents in plants, it has been proposed that BChE might be a naturally developed 
protecting enzyme against these toxicants (Antokhin et al., 2010). Apart from that, there 
has been some evidence that neuronal BChE may play a role in certain non-cholinergic 
pathways such as cell differentiation (Giacobini, 2001). 
 
 
Figure 2.2. Schematic representation of AChE action (Katzung et al., 2004) 
 
Previous studies revealed that as the AD progresses, the activity of AChE decreases 
whereas the activity of BChE remains unaffected or even increases (Giacobini, 2004). 
In the brain of advanced staged AD patients, BChE can compensate for AChE when the 
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activity of AChE is inhibited. Thus, BChE hydrolyzes the already depleted levels of 
ACh in these patients (Xie et al., 2000; Greig et al., 2005). It has been also proposed 
that individuals with low-activity of BChE can sustain cognitive functions better 
comparing to individuals with normal BChE activity (Holmes et al., 2005). Therefore, 
inhibitors with good balance between AChE and BChE inhibitory activity are valuable 
therapeutic targets in AD therapy. 
 
2.2.2. Structural specifications 
The overall architecture of the AChE and BChE enzymes is quite similar. The active 
site is located at the bottom of a 20 Å deep cavity named as “aromatic gorge”. Substrate 
and inhibitor guidance down the aromatic gorge is facilitated by hydrophobic 
interactions with aromatic residues lining the gorge wall such as phenylalanine (Phe), 
tryptophan (Trp) and tyrosine (Tyr) (Koellner et al., 2002). The overall structure of 
human AChE (hAChE) is very similar to that of Torpedo californica (TcAChE), 
whereby only the residues numbering are different. On the other hand, in the active site 
of BChE, aromatic residues such Trp and Phe, are replaced with hydrophobic ones 
including leucine (Leu) and valine (Val), making BChE more appropriate to 
accommodate bulkier substrates and inhibitors (Nicolet et al., 2003).  
 
2.2.3. Residue compositions of the active site gorge  
Active site gorge of AChE and BChE can be classified into five regions, namely the 
catalytic triad, oxyanion hole, acyl pocket, choline binding site, and peripheral anionic 
site. The active site is located at the bottom of the gorge, lying 20 Å below the surface. 
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The catalytic triad is the most important site of the enzymes, where the hydrolysis of 
acetylcholine takes place. Both AChE and BChE possess the catalytic triad (CT), which 
is composed of Ser200, His440 and Glu327 residues in TcAChE and His438, Ser198 
and Glu325 in hBChE (Sussman et al., 1991). The mechanism of substrate 
complexation to CT is plausibly via nucleophilic attack of serine hydroxyl moiety to 
carbonyl group of acetylcholine to give an acyl-enzyme intermediate. In the next step, 
water molecule deacylates serine by hydrolyzing its ester linkage of the substrate and 
converts acetylcholine to acetic acid and choline (Figure 2.3).  
 
 
Figure 2.3. Acetylcholine hydrolysis in AChE active site (ATSDR, 2013) 
 
Four other binding sub-sites play important role for guiding, orientation and insertion of 
the choline substrate in the catalytic cavity (Figure 2.4). Using TcAChE residue 
numbering, the functions of these sub-sites are described as follows:  
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(i) A three-pronged “oxyanion hole” formed by the amides backbone of Gly118, 
Gly119, and Ala201, stabilizes the negative charge developed at the C=O moiety of the 
substrate in the acylation/de-acylation process (Harel et al., 1996). 
 
(ii) A concave hydrophobic pocket (acyl-binding pocket) consisting of residues 
Phe288 and Phe290 is located in the so-called acyl loop, in which the acetyl or 
propanoyl moiety of the substrate is bound (Pezzementi et al., 2011).  
 
(iii) While the catalytic triad hydrolyzes the ester bond, the anionic site interacts with 
the acetylcholine quaternary ammonium atom and is responsible for its correct 
orientation. The aromatic rings of Trp84 and Phe330 at “choline binding site or α-
anionic site” of the enzyme stabilize the quaternary ammonium function of the choline 
moiety through cation-π interactions (Harel et al., 1993).  
 
 (iv) A peripheral anionic site ( anionic site), composed of aromatic Tyr 70, Asp72, 
Tyr 121, Trp279 and Tyr 334 residues guides the substrate to catalytic triad (Çokuğraş, 
2003). The peripheral anionic site is located 15Å above the active site, close to the 
mouth of the gorge.  
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Figure 2.4. Active site residue compositions in Torpedo californica AChE  (Dvir et al., 
2010) 
 
The enzyme active site gorge residue compositions of TcAChE, hAChE and hBChE are 
summarized in Table 2.1.  The overall structure of human AChE (hAChE) and Torpedo 
californica (TcAChE) are similar, they only differ in the residues numbering. On the 
other hand, in the active site of BChE, aromatic residues such Trp and Phe, are replaced 
with hydrophobic ones (Cheung et al., 2012). 
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2.2.4. Cholinesterase inhibitors 
Cognitive impairment is the most prominent and clinically relevant feature of AD. 
Cholinesterase inhibitors act by inhibiting cholinesterase enzymes from hydrolyzing 
acetylcholine, thus restoring the cognitive abilities in AD patients (Posner et al., 2013). 
To date, there are few prominent cholinesterase inhibitors available, namely tacrine, 
physostigmine, rivastigmine, donepezil, galanthamine and huperzine A, which 
structures are depicted in Figure 2.5. 
 
Tacrine or tetrahydroaminoacridine was the first FDA approved drug for the treatment 
of mild or moderate AD. Tacrine is a centrally acting, reversible AChE inhibitor, which 
exhibit a variety of pharmacological properties including interacting with nicotinic 
Table 2.1: Residue compositions of the enzyme active sites in TcAChE, hAChE and hBChE 
Site name 
Residue composition  
in TcAChE 
(Cheung et al., 2012) 
Residue composition  in 
hAChE 
(Cheung et al., 2012) 
Residue composition  in 
human BChE 
(Nicolet et al., 2003) 
Catalytic triad 
Ser200, His440 
&Glu327 
Ser203, His447 &   
Glu201 
His438, Ser198 & 
Glu325 
Choline binding 
site (α-anionic site) 
Trp84 & Phe330 Trp86 & Phe338 Trp82 & Phe329 
Acyl-binding 
pocket 
Phe288 & Phe290 Phe295 & Phe297 Leu286 & Val288 
Oxyanion hole 
Gly118, Gly119 & 
Ala201 
Gly121, Gly122 & 
Ala204 
Gly116, Gly117& Ala199 
Peripheral anionic 
site (β-anionic site) 
Tyr70, Asp72, Tyr121, 
Trp279 & Tyr334 
Tyr72, Asp74, Tyr124, 
Trp286 & Tyr341 
Trp231 & Phe398 
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receptors (Svensson, 2000). Tacrine is not prescribed clinically after multiple reports on 
its severe hepatotoxicity. 
 
Physostigmine is a competitive inhibitor of the AChE with the ability to diffuse 
through the blood brain barrier. It has been suggested as an alternative for protection 
against organophosphate brain toxicity as well as symptomatic treatment of AD. The 
therapeutic use of physostigmine is limited due to its biological constraints such as short 
elimination half-life, narrow effective dose range, low in vivo stability and low oral 
bioavailability (Walter et al., 1995). 
 
Rivastigmine (Exelon) is a novel carbamate type, reversible dual cholinesterase 
inhibitor used for symptomatic treatment of mild to moderate dementia in AD and 
idiopathic Parkinson’s disease. This inhibitor displays speciﬁc activity for central AChE 
over peripheral AChE (Kumar et al., 2009; Thomas et al., 2012). Adverse effects of 
rivastigmine are generally those associated with a second generation AChE inhibitor, in 
particular gastrointestinal effects, such as nausea and vomiting (Blesa González et al., 
2011). A new rivastigmine formulation has recently been developed in the form of 
transdermal patches, which provide a stable release of drug over time (Wentrup et al., 
2009). It is a safe, well tolerated system, which at the same time allows good adherence 
and effective drug penetration via the skin, with good local tolerability, ensuring ease of 
use together with optimized pharmacokinetics (Farlow et al., 2009). 
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Galanthamine, a tertiary alkaloid extracted from Galanthus and Narcissus species 
(Amaryllidaceae), is a competitive and reversible AChE inhibitor. In addition to 
inhibition of AChE, galanthamine interacts allosterically with nicotinic ACh receptors 
to potentiate the action of agonists of these receptors and ampliﬁes the ACh response by 
increasing ACh release (Samochocki et al., 2003; Nakao et al., 2008). Galanthamine 
has more than a 10-fold selectivity for AChE in contrast to BChE. The inhibition of 
AChE ceases 24 hours after the discontinuing galanthamine, therefore anesthetic agents 
and muscle relaxants, can be safely administered within a short period of stopping 
galanthamine (Coyle et al., 2001).  
 
Donepezil is a reversible and non-competitive cholinesterase inhibitor for the treatment 
of AD. It is a selective inhibitor toward AChE rather than BChE. This drug was 
demonstrated to be potent and selective toward brain AChE with lower adverse effects 
in comparison to tacrine (Yu et al., 2005). Several studies have demonstrated its 
efficacy in slowing the deterioration of cognitive function and its safety in long-term 
treatment. This drug has been shown to be effective for mild-to-moderate AD, and the 
start of treatment at earlier stage has been recommended (Zhang et al., 2007). 
 
Huperzine A, a novel Lycopodium alkaloid discovered from the Chinese folk medicine 
Huperzia serrata, has been found to inhibit AChE selectively and possess well tolerated 
properties that may be especially suitable for AD treatment (Zhao et al., 2002). 
Huperzine A is approved by the United States Food and Drug Administration as a 
dietary supplement for memory improvement and has been employed for centuries to 
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treat swelling, fever and blood disorders in China. Studies had showed its effectiveness 
to improve cognitive abilities in AD patients (Wang et al., 2009). 
 
 
Figure 2.5. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease 
 
2.3. Molecular docking 
Molecular docking is a process that predicts the conformation of a ligand within the 
active site of a receptor or enzyme and finds the lowest energy binding modes between 
them. It has become a useful tool in drug discovery efforts and is a primary component 
in many drug discovery programs (Kitchen et al., 2004). Pioneering research works in 
the area of molecular docking date back into the early 1980s. However, it took at least a 
decade for this technology to become popular among computational chemists and 
pharmaceutical researchers (Kuntz et al., 1982). Molecular docking procedure typically 
consists of two interrelated task: (i) to sample possible lowest energy conformational 
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states of the protein-ligand complex and (ii) to calculate of the free energy of these 
complex to produce a score, which can be further correlated to biological activities or 
other functions, the so-called scoring (Novikov et al., 2009). Docking simulation or in 
silico methodology is a valuable tool in investigation of the binding orientation of 
probable active ligands inside the active site of a specified protein from a particular 
library of compounds (McInnes, 2007). 
 
2.3.1. The role of molecular docking in cholinesterase inhibitors design 
The active site of AChE and BChE enzymes are composed of 5 major sub-sites, namely, 
peripheral anionic site (PAS), acyl binding pocket, choline binding site, oxyanion hole 
and catalytic triad. Compounds inhibiting ChE can be divided into three particular 
groups, which are 
(i)  Compounds binding at catalytic triad of the enzyme (e.g. nerve agents). 
(ii) Compounds interacting with the choline binding site of the enzyme (e.g. 
galanthamine).  
(iii) compounds binding at the peripheral anionic site of the enzyme (e.g. huperzine A). 
 
The catalytic triad binding inhibitors are the compounds with the chemical structure of 
organophosphorus or carbamate derivatives mainly including toxins, chemical warfare 
agents or pesticides. These compounds interact with serine residue in the catalytic triad 
of the enzyme, providing stable, irreversible esters (Bajgar, 2004). On the other hand, 
inhibitors binding to the choline binding site of the enzyme, typically contain condensed 
aromatic cores (e.g. galanthamine). In comparison to the catalytic triad inhibitors, the 
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compounds interact with the choline binding site are reversible inhibitors (Pohanka, 
2011). 
 
The peripheral anionic site is the main target of newly synthesized drugs for AD 
treatment. Studies showed that the deposition of amyloid plaque in AD might be 
accelerated or even triggered by interaction of β-amyloid with the peripheral anionic 
site of the enzyme. Thus, inhibition of the peripheral anionic site not only improve the 
symptomatic effects of AD due to the enhancement of acetylcholine availability but also 
slows down the deposition of β-amyloid plaques, as one of the major pathological 
hallmarks of AD (Berson et al., 2008; Arce et al., 2009). Moreover, drugs binding to the 
peripheral anionic site as well as choline binding site (e.g. donepezil, galanthamine) 
inhibit AChE more effectively.  
 
Thus, the therapeutic features of newly synthesized inhibitors can be demonstrated by in 
silico interaction analysis with the amino acid residues composing active site of 
cholinesterase enzymes prior to employing expensive and time-consuming in vivo 
techniques. 
 
2.4. Medicinal chemistry 
Medicinal chemistry is the science that deals with discovery and design of new 
therapeutic chemicals and their development into useful medicines (Lednicer, 2009). It 
may involve isolation of compounds from nature or the synthesis of new molecules, 
investigation of the relationships between the structure of molecules and their activity, 
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and elucidation of the interactions between this molecules and the receptors of various 
kind (Bauer, 1969).  
 
Medicinal chemistry has been practiced for several thousand years. The earliest written 
records of Chinese, Indians, South Americans and Mediterranean civilizations described 
the therapeutic effect of different plants (Sneader et al., 1985). However, the modern 
therapeutic is considered to have begun with an extract of foxglove plant for the 
treatment of dropsy (congestive heart failure) in 1785 by Withering (Withering, 1785). 
As a result of advances made in synthesis and separation methods as well as 
biochemical techniques since the late 1940s, a rational approach to design, synthesis and 
chemical modification to improve or change their medicinal properties was established.  
 
2.4.1. The role of organic synthesis in drug discovery 
Generally, drugs are not discovered. What is more likely to be discovered is known as a 
lead compound. The lead is a prototype compound that has a number of attractive 
pharmacological activities and pharmaceutical applications, but may have other 
undesirable properties including high toxicity, absorption difficulties, insolubility or 
metabolism difficulties. The structure of the lead compound is modified by organic 
synthesis to amplify the desired activities and to minimize or eliminate the unwanted 
properties to prepare a drug candidate, which is a compound appropriate for extensive 
biological, pharmacological and animal studies (Lednicer, 2009).  
 
